Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Probiotics for the Oncological Patients

Project description

A novel probiotics solution for cancer patients

Cancer treatment is associated with many side effects, including loss of intestinal integrity and disturbance in the gut microbiome. The key objective of the EU-funded ONCOTICS project is to bring a probiotics product into the market for oncology patients to counteract treatment-related disruption. The probiotic supplementation solution overcomes the administration of live bacteria through gentle lysis preserving, however, the biologically active molecules that are needed for intestinal mucosa homeostasis and for fighting off pathogenic bacteria. Alongside experimental validation of the properties of the ONCOTICS solution, the project will undertake commercial and technical viability studies.

Objective

The main objective of this project is to perform the technological/comercial and economical viability of the newly developped very gentle form of microbial lysis which preserves the biologically active molecules of probiotic bacteria that favorably affects the cells of the intestinal mucosa and the mucosal immune system. This newly designed probioticsmodify the integrity of the intestinal mucosa damaged as a result of oncological treatment, to suppress inflammatory changes in the mucous membrane and, at the same time, to contribute to stabilization by the treatment of the disrupted microbiome. The ONCOTICS introduces novel treatment of intestines infections which brings : - Unique probiotical lysates product improving the oncology patients life comfort - New approach for elemination of syndrom leaky gut in oncological patients - Very safe gut barrier regeneration compared with standard probiotics, which can cuase sepsis - New patented technology for production of probiotics lysates - Novel therapy opening new markets

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

PHARMACEUTICAL BIOTECHNOLOGY SRO
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 50 000,00
Address
SLEZSKA 949/32
12000 PRAHA
Czechia

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Česko Praha Hlavní město Praha
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 71 429,00
My booklet 0 0